Last reviewed · How we verify

Standard of Care COPD Treatment

AstraZeneca · Phase 3 active Small molecule

Standard of Care COPD Treatment is a Muscarinic antagonist Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD).

Tiotropium bromide is a long-acting muscarinic antagonist that relaxes bronchial smooth muscle and increases lung function in patients with COPD.

Tiotropium bromide is a long-acting muscarinic antagonist that relaxes bronchial smooth muscle and increases lung function in patients with COPD. Used for Chronic obstructive pulmonary disease (COPD).

At a glance

Generic nameStandard of Care COPD Treatment
SponsorAstraZeneca
Drug classMuscarinic antagonist
TargetM3 muscarinic receptor
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 3

Mechanism of action

Tiotropium bromide works by blocking the action of acetylcholine at muscarinic receptors in the lungs, leading to bronchodilation and improved lung function. This results in increased FEV1 and improved symptoms in patients with COPD.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Standard of Care COPD Treatment

What is Standard of Care COPD Treatment?

Standard of Care COPD Treatment is a Muscarinic antagonist drug developed by AstraZeneca, indicated for Chronic obstructive pulmonary disease (COPD).

How does Standard of Care COPD Treatment work?

Tiotropium bromide is a long-acting muscarinic antagonist that relaxes bronchial smooth muscle and increases lung function in patients with COPD.

What is Standard of Care COPD Treatment used for?

Standard of Care COPD Treatment is indicated for Chronic obstructive pulmonary disease (COPD).

Who makes Standard of Care COPD Treatment?

Standard of Care COPD Treatment is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What drug class is Standard of Care COPD Treatment in?

Standard of Care COPD Treatment belongs to the Muscarinic antagonist class. See all Muscarinic antagonist drugs at /class/muscarinic-antagonist.

What development phase is Standard of Care COPD Treatment in?

Standard of Care COPD Treatment is in Phase 3.

What are the side effects of Standard of Care COPD Treatment?

Common side effects of Standard of Care COPD Treatment include Cough, Dysphonia, Headache, Nausea, Dyspnea.

What does Standard of Care COPD Treatment target?

Standard of Care COPD Treatment targets M3 muscarinic receptor and is a Muscarinic antagonist.

Related